Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Social Psychiatry and Psychiatric Epidemiology
Published in: Social Psychiatry and Psychiatric Epidemiology 7/2010

01-07-2010 | Original Paper

Cost-effectiveness analysis of an occupational therapy-led lifestyle approach and routine general practitioner’s care for panic disorder

Authors: Rodney A. Lambert, Paula Lorgelly, Ian Harvey, Fiona Poland

Published in: Social Psychiatry and Psychiatric Epidemiology | Issue 7/2010

Login to get access

Abstract

Objective

To assess the cost-effectiveness of an occupational therapy-led lifestyle approach to treating panic disorder in primary care compared with routine general practitioner’s (GP) care. The burden of mental health disorders is considerable. Cost-effective interventions are necessary to alleviate some of these burdens. Habitual lifestyle behaviours influence mood, although to date mainly single lifestyle factor trials have been conducted to examine the effects on anxiety.

Methods

An economic evaluation was conducted alongside an unblinded pragmatic randomised controlled trial with assessment at 5 and 10 months. Costs and consequences, as measured by the Beck anxiety inventory (BAI) and quality adjusted life years (QALYs), were compared using incremental cost-effectiveness ratios (ICERs).

Results

The occupational therapy-led lifestyle intervention was more costly than routine GP care at both 5 and 10 months. Significant outcome improvements were evident at 5 months when using the BAI, although these were not maintained at 10 months. Small differences in mean QALYs were found. The estimated ICER was £36 per BAI improvement for 5 months and £39 for 10 months, and £18,905 per QALY gained for 5 months and £8,283 for 10 months.

Conclusions

If the maximum willingness to pay per additional QALY is £30,000, then there is an 86% chance that a lifestyle intervention may be considered to be value-for-money over 10 months.
Literature
1.
Alsene K, Deckert J, Sand P, de Wit H (2003) Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 28:1694–1702CrossRefPubMed
2.
American Psychiatric Association (2000) Diagnostic & statistical manual of mental disorders; DSM-IV TR. American Psychiatric Association, Washington, DC
3.
American Psychiatric Association (2000) Practice guidelines for the treatment of psychiatric disorders: compendium 2000. American Psychiatric Association, Washington, DC
4.
Andrews G (2003) Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiat 37:641
5.
Asmundson GJ, Larsen DK, Stein MB (1998) Panic disorder and vestibular disturbance: an overview of empirical findings and clinical implications. J Psychosom Res 44:107–120CrossRefPubMed
6.
Barlow JH, Ellard DR, Hainsworth JM, Jones FR, Fisher A (2005) A review of self-management interventions for panic disorders, phobias and obsessive-compulsive disorders. Acta Psychiatr Scand 111:272–285CrossRefPubMed
7.
Beck AT, Steer RA (1993) Beck anxiety inventory manual. The Psychological Corporation, San Antonio
8.
9.
Biber B, Alkin T (1999) Panic disorder subtypes: differential responses to CO2 challenge. Am J Psychiatry 156:739–744PubMed
10.
Bower P, Richards D, Lovell K (2001) The clinical and cost-effectiveness of self-help treatments for anxiety and depressive disorders in primary care: a systematic review. Br J Gen Pract 51:838–845PubMed
11.
Brazier J, Roberts J, Tsuchiya A, Busschbach J (2004) A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 13:873–884CrossRefPubMed
12.
Briggs AH, Wonderling DE, Mooney CZ (1997) Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 6:327–340CrossRefPubMed
13.
14.
Brown TA, DiNardo PA, Barlow DH (1994) Anxiety disorders interview schedule for DSM-IV (Adult version). Graywind Publications Incorporated, New York
15.
Callaghan P (2004) Exercise: a neglected intervention in mental health care? J Psychiatr Ment Health Nurs 11:476–483CrossRefPubMed
16.
Clark DM, Salkovskis PM, Hackmann A, Wells A, Ludgate J, Gelder M (1999) Brief cognitive therapy for panic disorder: a randomized controlled trial. J Consult Clin Psychol 67:583–589CrossRefPubMed
17.
Davids E, Muller MJ, Rollmann N, Burkart M, Regier-Klein E, Szegedi A, Benkert O, Maier W (2002) Syndrome profiles in alcoholism and panic disorder with or without agoraphobia: an explorative family study. Prog Neuropsychopharmacol Biol Psychiatry 26:1079–1087CrossRefPubMed
18.
Department of Health (1999) National service framework for mental health: modern standards & service models. Department of Health, London
19.
Department of Health (2007) Health is global: proposal for a UK government-wide strategy. Department of Health, London
20.
Dolan P, Gudex C, Kind P, Williams A (1995) Social tariff for EuroQol : results from a UK general population survey. Centre for Health Economics, University of York, York
21.
Duncan CE (2003) Monthly index of medical specialities (MIMS). Haymarket Medical Publications Ltd, London
22.
Falk Dahl CA, Dahl AA (2009) Lifestyle and social network in individuals with high level of social phobia/anxiety symptoms: a community-based study. Soc Psychiatry Psychiatr Epidemiol (in press)
23.
Frank E, Shear MK, Rucci P, Banti S, Mauri M, Maser JD, Kupfer DJ, Miniati M, Fagiolini A, Cassano GB (2005) Cross-cultural validity of the structured clinical interview for panic-agoraphobic spectrum. Soc Psychiatry Psychiatr Epidemiol 40:283–290CrossRefPubMed
24.
Glick H, Doshi J, Sonnad S, Polsky D (2007) Transferability of the results from trials: economic evaluation in clinical trials. Oxford University Press, Oxford
25.
Gulpek D, Bayraktar E, Akbay SP, Capaci K, Kayikcioglu M, Aliyev E, Soydas C (2004) Joint hypermobility syndrome and mitral valve prolapse in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 28:969–973CrossRefPubMed
26.
Hamilton SP, Fyer AJ, Durner M, Heiman GA, Baisre DL, Hodge SE, Knowles JA, Weissman MM (2003) Further genetic evidence for a panic disorder syndrome mapping to chromosome 13q. Proc Natl Acad Sci USA 100:2550–2555CrossRefPubMed
27.
Heuzenroeder L, Donnelly M, Haby MM, Mihalopoulos C, Rossell R, Carter R, Andrews G, Vos T (2004) Cost-effectiveness of psychological and pharmacological interventions for generalised anxiety disorder and panic disorder. Aust N Z J Psychiatry 38:602–612PubMed
28.
Horwath E, Adams P, Wickramaratne P, Pine D, Weissman MM (1997) Panic disorder with smothering symptoms: evidence for increased risk in first-degree relatives. Depress Anxiety 6:147–153CrossRefPubMed
29.
Isensee B, Wittchen HU, Stein MB, Hofler M, Lieb R (2003) Smoking increases the risk of panic: findings from a prospective community study. Arch Gen Psychiatry 60:692–700CrossRefPubMed
30.
31.
Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverly C, Parry G, Rooney G, Sutcliffe P (2006) Computerized cognitive behavior therapy for depression and anxiety update: a systematic review and economic evaluation. Health Technol Assess 10:1–70
32.
Kaltenthaler E, Shackley P, Stevens K, Beverley C, Parry G, Chilcott J (2002) A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety. Health Technol Assess 6:1–89PubMed
33.
Katon W, Russo J, Sherbourne C, Stein MB, Craske M, Fan MY, Roy-Byrne P (2006) Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychol Med 36:353–363CrossRefPubMed
34.
Koh KB, Lee Y (2004) Reduced anxiety level by therapeutic interventions and cell-mediated immunity in panic disorder patients. Psychother Psychosom 73:286–292CrossRefPubMed
35.
Kumano H, Kaiya H, Yoshiuchi K, Yamanaka G, Sasaki T, Kuboki T (2004) Comorbidity of irritable bowel syndrome, panic disorder, and agoraphobia in a Japanese representative sample. Am J Gastroenterol 99:370–376CrossRefPubMed
36.
Lambert R, Caan W, McVicar A (2008) Influences of lifestyle and general practice (GP) care on the symptom profile of people with panic disorder. J Public Ment Health 7:18–24
37.
Lambert RA, Harvey I, Poland F (2007) A pragmatic, unblinded randomised controlled trial comparing an occupational therapy-led lifestyle approach and routine GP care for panic disorder treatment in primary care. J Affect Disord 99:63–71CrossRefPubMed
38.
Manca A, Hawkins N, Sculpher MJ (2005) Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 14:487–496CrossRefPubMed
39.
Mann R, Gilbody S, Richards D (2009) Putting the ‘Q’ in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures. Soc Psychiatry Psychiatr Epidemiol 44:569–578CrossRefPubMed
40.
March JS, Silva SG, Compton S, Shapiro M, Califf R, Krishnan R (2005) The case for practical clinical trials in psychiatry. Am J Psychiatry 162:836–846CrossRefPubMed
41.
Marciniak MD, Lage MJ, Dunayevich E, Russell JM, Bowman L, Landbloom RP, Levine LR (2005) The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depress Anxiety 21:178–184CrossRefPubMed
42.
Matthews JN, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. BMJ 300:230–235CrossRefPubMed
43.
Maunder RG (1998) Panic disorder associated with gastrointestinal disease: review and hypotheses. J Psychosom Res 44:91–105CrossRefPubMed
44.
McCrone P, Knapp M, Proudfoot J, Ryden C, Cavanagh K, Shapiro DA, Ilson S, Gray JA, Goldberg D, Mann A, Marks I, Everitt B, Tylee A (2004) Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 185:55–62CrossRefPubMed
45.
McHugh RK, Otto MW, Barlow DH, Gorman JM, Shear MK, Woods SW (2007) Cost-efficacy of individual and combined treatments for panic disorder. J Clin Psychiatry 68:1038–1044CrossRefPubMed
46.
Mulder M, Ranchor AV, Sanderman R, Bouma J, van den Heuvel WJ (1998) The stability of lifestyle behaviour. Int J Epidemiol 27:199–207CrossRefPubMed
47.
Muller V, Birbaumer N, Preissl H, Braun C, Lang F (2002) Effects of water on cortical excitability in humans. Eur J Neurosci 15:528–538CrossRefPubMed
48.
Nadiga DN, Hensley PL, Uhlenhuth EH (2003) Review of the long-term effectiveness of cognitive behavioral therapy compared to medications in panic disorder. Depress Anxiety 17:58–64CrossRefPubMed
49.
Netten A, Rees T, Harrison G, PSSRU (2002) Unit costs of health and social care 2002. Personal Social Services Research Unit, Canterbury
50.
National Institute for Health and Clinical Excellence (NICE) (2004) Clinical guidelines for the management of panic disorder and generalised anxiety disorder: consultation document. ScHARR, University of Sheffield
51.
Papakostas GI, Ongur D, Iosifescu DV, Mischoulon D, Fava M (2004) Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. Eur Neuropsychopharmacol 14:135–142CrossRefPubMed
52.
Patel A, Knapp M, Evans A, Perez I, Kalra L (2004) Training care givers of stroke patients: economic evaluation. BMJ 328:1102CrossRefPubMed
53.
Perna G, Dario A, Caldirola D, Stefania B, Cesarani A, Bellodi L (2001) Panic disorder: the role of the balance system. J Psychiatr Res 35:279–286CrossRefPubMed
54.
Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 323:1300–1303CrossRefPubMed
55.
Roberge P, Marchand A, Reinharz D, Savard P (2008) Cognitive-behavioral treatment for panic disorder with agoraphobia: a randomized, controlled trial and cost-effectiveness analysis. Behav Modif 32:333–351CrossRefPubMed
56.
Slattery MJ, Klein DF, Mannuzza S, Moulton JLIII, Pine DS, Klein RG (2002) Relationship between separation anxiety disorder, parental panic disorder, and atopic disorders in children: a controlled high-risk study. J Am Acad Child Adolesc Psychiatry 41:947–954CrossRefPubMed
57.
Smoller JW, Gardner-Schuster E, Covino J (2008) The genetic basis of panic and phobic anxiety disorders. Am J Med Genet C Semin Med Genet 148C:118–126CrossRefPubMed
58.
The Sainsbury Centre for Mental Health (2003) The economic and social costs of mental illness. Policy Paper 3. The Sainsbury Centre for Mental Health, London
59.
van Hout BA, Al MJ, Gordon GS, Rutten FF (1994) Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 3:309–319CrossRefPubMed
60.
Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lepine JP, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen HU, Yeh EK (1997) The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54:305–309PubMed
61.
Weissman MM, Fyer AJ, Haghighi F, Heiman G, Deng Z, Hen R, Hodge SE, Knowles JA (2000) Potential panic disorder syndrome: clinical and genetic linkage evidence. Am J Med Genet 96:24–35CrossRefPubMed
62.
WHO (2004) Prevention of mental disorders: effective interventions and policy options. World Health Organisation, Geneva
63.
Yeragani VK, Tancer M, Uhde T (2003) Heart rate and QT interval variability: abnormal alpha-2 adrenergic function in patients with panic disorder. Psychiatry Res 121:185–196CrossRefPubMed
Metadata
Title
Cost-effectiveness analysis of an occupational therapy-led lifestyle approach and routine general practitioner’s care for panic disorder
Authors
Rodney A. Lambert
Paula Lorgelly
Ian Harvey
Fiona Poland
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Social Psychiatry and Psychiatric Epidemiology / Issue 7/2010
Print ISSN: 0933-7954
Electronic ISSN: 1433-9285
DOI
https://doi.org/10.1007/s00127-009-0114-5

Other articles of this Issue 7/2010

Social Psychiatry and Psychiatric Epidemiology 7/2010 Go to the issue

Original Paper

Mental illness stigma and willingness to seek mental health care in the European Union

Original Paper

Attitudes and physical distance to an individual with schizophrenia: the moderating effect of self-transcendent values

Original Paper

Personality traits and mental health of severe drunk drivers in Sweden

Original Paper

Anxiety and depressive symptoms related to parenthood in a large Norwegian community sample: the HUNT2 study

Original Paper

Sexual problems in schizophrenia: prevalence and characteristics. A cross sectional survey

Original Paper

Sri Lankan doctors’ and medical undergraduates’ attitudes towards mental illness